SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (BSD) (NASDAQ:BSDM) announced today that Lancet Oncology, the premiere worldwide journal for original oncology research, has published the results of a Phase III clinical study of hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy for the treatment of high-risk soft-tissue sarcoma cancer (STS) patients, “Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study”. (The Lancet Oncology, Early Online Publication, 29 April 2010, doi:10.1016/S1470-2045(10)70071-1.)
